Adjuvant Pembrolizumab Offers Improved OS in KEYNOTE-564 Trial of ccRCC
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.
For decades, treatment for cancer was a blunt tool — everyone got the same, left to fight for their life chances against sometimes impossible odds.…
A recent cross-sectional study assessed the rates of breast, cervical, and colorectal cancer screenings in Federally Qualified Health Centers compared with overall screening rates in…
Acute Lymphocytic Leukemia statistics
Fred Hutch prostate cancer and RNA translation expert Dr. Andrew Hsieh was named a Harrington Discovery Institute 2024 Scholar-Innovator. The award will support Hsieh’s efforts…
Dr. Trisha Amboree explains the findings of the research and how it can help mitigate health disparities.
The 2024 SITC Election takes place May 2–16, 2024.
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb’s Opdivo (nivolumab) in combination with…
The CT Screening Symposium is a 1-day, immersive, in-person event being featured at WCLC 2024 focused on lung cancer screening technologies and best practices. …
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other…